- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BAUDAX BIO Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 28,300 | -1,05 % | MPH Health Care: Dividende steigt kräftig | Die MPH Health Care AG hat im ersten Quartal 2026 einen Verlust von 52,0 Millionen Euro verbucht nach 20,0 Millionen Euro im Vorjahresquartal. Ursache ist nach Angaben des Berliner Unternehmens die... ► Artikel lesen | |
| SOLIGENIX | 0,411 | +0,12 % | SOLIGENIX, INC. - 8-K, Current Report | ||
| CHARLOTTES WEB | 0,290 | 0,00 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Provides Update on Diverging Hemp Policies: Federal Momentum Builds as California Restricts Therapeutic Hemp Product Access | Louisville, Colorado--(Newsfile Corp. - June 26, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 4,358 | 0,00 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces ... | - Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for... ► Artikel lesen | |
| ALLARITY THERAPEUTICS | 1,290 | -0,77 % | Allarity Therapeutics, Inc. - 8-K, Current Report | ||
| AVENUE THERAPEUTICS | - | - | Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease | ATX-04 is a selective ß2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE... ► Artikel lesen | |
| APTORUM GROUP | 0,762 | -1,50 % | Aptorum Group Ltd: Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer's Disease Biomarkers | ||
| PROCESSA PHARMACEUTICALS | 1,920 | +3,23 % | RedChip Companies, Inc.: Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA)... ► Artikel lesen | |
| PETROS PHARMACEUTICALS | - | - | Petros Pharmaceuticals, Inc. - 8-K, Current Report | ||
| CDT EQUITY | 0,628 | -1,26 % | CDT Equity Inc.: CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development | ||
| PRF TECHNOLOGIES | 1,550 | +2,65 % | PRF Technologies Ltd.: PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark | TEL AVIV, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company"), a clinical-stage specialty pharmaceutical company focused on reformulating established... ► Artikel lesen | |
| BAYER | 47,000 | 0,00 % | Bayer und PORR werden für Produktionsanlage ausgezeichnet | ||
| MERCK KGAA | 145,65 | -0,92 % | DZ BANK stuft MERCK KGAA auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Merck KGaA auf "Kaufen" mit einem fairen Wert von 153 Euro belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,390 | 0,00 % | Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? | ||
| JOURNEY MEDICAL | 6,620 | 0,00 % | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen |
Das Unternehmen BAUDAX BIO INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BAUDAX BIO INC finden Sie auf Wallstreet Online.